Akèy › Kansè fwa (Kasinòm epatoselilè) › Arizona
Etid klinik pou Kansè fwa (Kasinòm epatoselilè) nan Arizona
17 etid pou Kansè fwa (Kasinòm epatoselilè) ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
A Phase 1 Study of the Safety and Tolerability of CTX-10726
- Mayo Clinic Arizona, Phoenix
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07419841Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #67, Phoenix
- Exelixis Clinical Site #1, Tucson
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT05176483Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
- Research Facility, Phoenix
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06726161GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
- University of Arizona Cancer Center, Tucson
Ap rekriteFaz 1 bonè
Laj 18 a 99 · Tout sèks · Mizajou Sep 18, 2026 · NCT07627191A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- City of Hope Phoenix Cancer Center, Goodyear
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06427941Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- Research Site, Phoenix
- Research Site, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06921785A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors
- HonorHealth Research Institute, Scottsdale
Ap rekriteFaz 1/2
Laj 18 a 75 · Tout sèks · Mizajou Aug 19, 2026 · NCT07636785FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Mayo Clinic, Phoenix
- Honor Health, Scottsdale
- Arizona Cancer Center at University of Arizona, Tucson
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer
- Mayo Clinic in Arizona, Scottsdale
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 4, 2026 · NCT05168163A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Phoenix
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT06600321Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
- Southern Arizona VA Health Care System, Tucson, AZ, Tucson
Ap rekrite
Laj 18 a 75 · Tout sèks · Mizajou Jun 17, 2026 · NCT05486572Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- Mayo Clinic in Arizona, Phoenix
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Mar 12, 2026 · NCT06349642Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Scottsdale Medical Imaging, LLC, Scottsdale
Ap rekriteFaz 4
Laj 18 a 64 · Tout sèks · Mizajou Jan 22, 2026 · NCT04373564A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- Research Site 111, Tucson
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 21, 2025 · NCT05914116SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scottsdale
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Mayo Clinic in Arizona, Scottsdale
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 25, 2024 · NCT05824975Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
- HonorHealth Research Institute, Scottsdale
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 8, 2024 · NCT04282044Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.